NO20092019L - Behandling av gjennomtrengende utviklingsforstyrrelser - Google Patents

Behandling av gjennomtrengende utviklingsforstyrrelser

Info

Publication number
NO20092019L
NO20092019L NO20092019A NO20092019A NO20092019L NO 20092019 L NO20092019 L NO 20092019L NO 20092019 A NO20092019 A NO 20092019A NO 20092019 A NO20092019 A NO 20092019A NO 20092019 L NO20092019 L NO 20092019L
Authority
NO
Norway
Prior art keywords
disorder
developmental disorders
pervasive developmental
treatment
pdds
Prior art date
Application number
NO20092019A
Other languages
English (en)
Inventor
Magali Haas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092019L publication Critical patent/NO20092019L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse er en fremgangsmåte for behandling av pervasive utviklingsforstyrrelser (PDD'er) som inkluderer; autistisk forstyrrelse, Aspergers syndrom, barnedisintegrativ forstyrrelse (CDD), Rett's forstyrrelse og PDD-ikke ellers spesifisert (PPD-NOS) som innbefatter administrering til et subjekt som trenger det en teapeutisk effektiv mengde av en eller flere karbamatforbindelser med formel 1 og/eller formel 2 som definert heri og vist nedenfor. Foreliggende oppfinnelse angår en fremgangsmåte for behandling av pervasive utviklingsforstyrrelser (PDD'er) som inkluderer; autistisk forstyrrelse, Aspergers syndrom, barnedisintegrativ forstyrrelse (CDD), Rett's forstyrrelse og PDD-ikke ellers spesifisert (PPD-NOS), som inkluderer monoterapi og alternativ, kombinasjonsterapi med minst en ytterligere psykoaktiv medisinering.
NO20092019A 2006-10-31 2009-05-25 Behandling av gjennomtrengende utviklingsforstyrrelser NO20092019L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86359506P 2006-10-31 2006-10-31
PCT/US2007/081365 WO2008054984A1 (en) 2006-10-31 2007-10-15 Treatment of pervasive developmental disorders

Publications (1)

Publication Number Publication Date
NO20092019L true NO20092019L (no) 2009-06-23

Family

ID=39145417

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092019A NO20092019L (no) 2006-10-31 2009-05-25 Behandling av gjennomtrengende utviklingsforstyrrelser

Country Status (17)

Country Link
US (1) US20080103199A1 (no)
EP (1) EP2089011A1 (no)
JP (1) JP2010508354A (no)
KR (1) KR20090080105A (no)
CN (1) CN101568333A (no)
AU (1) AU2007313911A1 (no)
BR (1) BRPI0718323A2 (no)
CA (1) CA2667909A1 (no)
CO (1) CO6180427A2 (no)
EA (1) EA200970435A1 (no)
GT (1) GT200900112A (no)
IL (1) IL198488A0 (no)
MX (1) MX2009004798A (no)
NI (1) NI200900074A (no)
NO (1) NO20092019L (no)
WO (1) WO2008054984A1 (no)
ZA (1) ZA200903772B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
WO2010020585A1 (en) * 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
EP2601609B1 (en) 2010-08-02 2017-05-17 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP2773779B1 (en) 2011-11-04 2020-10-14 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US9517254B2 (en) * 2012-08-06 2016-12-13 S1 Biopharma, Inc. Treatment regimens
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
WO2014142547A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same
CA2996445A1 (en) 2014-09-05 2016-03-10 Eli Hatchwell Methods and compositions for inhibiting and treating neurological conditions
CN110290788A (zh) * 2016-12-14 2019-09-27 爱思开生物制药株式会社 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
FI4177356T3 (fi) 2018-08-08 2024-08-07 Pml Screening Llc Menetelmiä virustaudin kehittymisriskin arviointiin geenitestillä
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50676B (sr) * 2001-02-27 2010-06-30 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
DK1401424T3 (da) * 2001-02-27 2007-02-26 Ortho Mcneil Pharm Inc Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af psykotiske forstyrrelser
DE60220043T2 (de) * 2001-02-27 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder
PT1809273E (pt) * 2004-09-16 2010-05-10 Janssen Pharmaceutica Nv Utililização de 2-fenil-1,2-etanodiol-(di)carbamatos para tratamento de epileptogénese

Also Published As

Publication number Publication date
JP2010508354A (ja) 2010-03-18
US20080103199A1 (en) 2008-05-01
ZA200903772B (en) 2010-08-25
GT200900112A (es) 2010-05-18
IL198488A0 (en) 2010-02-17
WO2008054984A1 (en) 2008-05-08
MX2009004798A (es) 2009-08-12
EA200970435A1 (ru) 2009-10-30
CO6180427A2 (es) 2010-07-19
BRPI0718323A2 (pt) 2013-11-26
KR20090080105A (ko) 2009-07-23
NI200900074A (es) 2010-02-01
AU2007313911A1 (en) 2008-05-08
EP2089011A1 (en) 2009-08-19
CN101568333A (zh) 2009-10-28
CA2667909A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
MX2009004798A (es) Tratamiento de los trastornos generalizados del desarrollo.
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
BR112013031510A2 (pt) [1,3]oxazinas
NO20084931L (no) Farmasoytiske sammensetninger
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201200054A1 (ru) Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
DOP2006000170A (es) Nuevos derivados de espirocromanona
EA201200406A1 (ru) Соединения и композиции, которые являются модуляторами активности tlr
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
EA201290517A1 (ru) Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application